1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87–108. http://www.ncbi.nlm.nih.gov/pubmed/25651787 , https://www.colwiz.com/cite-in-google-docs/cid=colwizBiblio . Accessed 4 Mar 2015.
2. Lu C-L, Lang H-C, Luo J-C, Liu C-C, Lin H-C, Chang F-Y, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control CCC. 2010;21:269–74. http://www.ncbi.nlm.nih.gov/pubmed/19866363 , https://www.colwiz.com/cite-in-google-docs/cid=colwizBiblio . Accessed 1 Mar 2010.
3. Tachimori Y, Ozawa S, Numasaki H, Fujishiro M, Matsubara H, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus. 2016;13:110–137. http://link.springer.com/10.1007/s10388-016-0531-y , https://www.colwiz.com/cite-in-google-docs/cid=colwizBiblio . Accessed 29 Mar 2016.
4. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al., KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med. 2015;372:2521–32. http://www.ncbi.nlm.nih.gov/pubmed/25891173 , https://www.colwiz.com/cite-in-google-docs/cid=colwizBiblio . Accessed 25 Jun 2015.
5. Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non–small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:3713–17. http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-2998 , https://www.colwiz.com/cite-in-google-docs/cid=colwizBiblio . Accessed 1 Jun 2016.